Adicciones (remedios generales para)

The 2021 PMC clinical review identified low back pain and musculoskeletal pain as conditions studied in arnica clinical trials, and the German Commission E has approved topical arnica for rheumatic muscle pain. Topical arnica gel has been tested as an adjunct for musculoskeletal pain including the back, with some positive outcomes noted in trial summaries.

Oral ATP disodium has been studied in a randomized, double-blind, placebo-controlled trial specifically for subacute low back pain. Additionally, ATP capsules are registered in France for low back pain of muscular origin. The mechanism likely involves ATP's role as a local regulator of inflammation and nociception via purinergic receptors. Evidence remains limited to a small number of trials.

Boswellia serrata, the Indian frankincense tree, has substantial clinical evidence for musculoskeletal pain including low back pain. A 2020 systematic review and meta-analysis (7 RCTs, 545 patients) found Boswellia significantly reduced pain and improved joint function versus controls. A randomized, double-blind, placebo-controlled trial confirmed efficacy of a Boswellia-turmeric combination for chronic low back pain over 90 days.

Boswellic acids are the active pentacyclic triterpene acids in Boswellia serrata extracts. They selectively inhibit 5-lipoxygenase (5-LOX), reducing leukotriene production and NF-κB-mediated inflammation. Clinical RCTs and meta-analyses have documented their efficacy in reducing musculoskeletal pain, with specific trials demonstrating benefit in chronic low back pain.

Medical News Today cites a 2016 study showing camphor oil relieved lower back pain. Camphor is a common ingredient in OTC topical analgesics indicated for minor backache. Its analgesic mechanism involves TRPV1 desensitization and TRPA1 inhibition in sensory nerves.

Capsaicin, the active vanilloid alkaloid of capsicum, is supported by multiple RCTs for topical treatment of chronic nonspecific low back pain. It acts via TRPV1 receptor activation, depleting substance P from nociceptors to produce lasting desensitization. Double-blind trials with capsaicin plasters or creams showed statistically significant pain reduction versus placebo (p=0.002) in populations with chronic LBP.

Topical capsicum (Capsicum frutescens) preparations are supported by multiple RCTs and two Cochrane reviews for nonspecific chronic low back pain. A double-blind, placebo-controlled trial (n=154) found a capsicum plaster containing 11 mg capsaicinoids reduced pain by 42% versus 31% for placebo (p=0.002) over 3 weeks. Capsaicin depletes substance P from nociceptive C-fibers, producing reversible desensitization to pain.

Topical cayenne pepper cataplasms and capsaicin creams have been used in traditional medicine and evaluated in controlled studies for back pain. A PMC study specifically used cayenne pepper cataplasm for back pain and rheumatism. Capsaicin cream is used clinically for lower back pain via the same substance P depletion mechanism as other musculoskeletal pain.

Chondroitin sulfate, a structural glycosaminoglycan of articular cartilage and intervertebral disc, has been studied for low back pain associated with degenerative disc disease and spinal osteoarthritis. A 2022 meta-analysis (8 RCTs, 3,793 patients) found glucosamine-chondroitin combination significantly improved WOMAC scores versus placebo. Clinical evidence supports its use in chronic back pain related to disc and facet joint degeneration.

Spinal intervertebral discs are composed primarily of type I and type II collagen, and degenerative disc disease involves progressive collagen breakdown in the annulus fibrosus and nucleus pulposus. A randomized, double-blind, placebo-controlled trial found collagen peptide ingestion significantly improved functional limitations associated with lower back discomfort. Evidence is early-stage but mechanistically plausible and supported by at least one RCT.

Multiple randomised controlled trials demonstrate topical comfrey root extract significantly reduces acute upper and lower back pain versus placebo. A multicentre, double-blind, three-arm RCT (n=379) found a 35% comfrey root extract plus methyl nicotinate combination markedly superior to placebo on pain VAS during movement. The German Commission E and ESCOP monographs list low back pain among substantiated indications for topical comfrey root preparations.

Curcumin, the primary bioactive curcuminoid of turmeric, has documented efficacy in managing low back pain and musculoskeletal inflammation in RCTs. It inhibits COX-2, NF-κB, and 5-LOX pathways. Double-blind RCTs including a 90-day trial in chronic LBP patients (n=90) showed significant reductions in pain, disability, and inflammatory biomarkers versus placebo.

Curcuminoids—the collective mixture of curcumin, desmethoxycurcumin, and bis-desmethoxycurcumin from turmeric—underlie the anti-inflammatory effects demonstrated in RCTs for low back pain. Double-blind placebo-controlled trials using curcuminoid-standardized extracts show significant reductions in LBP pain scores, disability indices, and serum inflammatory biomarkers versus placebo.

Devil's Claw (Harpagophytum procumbens) is one of the best-studied herbal remedies for low back pain. The 2006 and 2014 Cochrane reviews found strong to moderate evidence that daily doses standardized to 50–100 mg harpagoside significantly reduced pain versus placebo. One high-quality RCT demonstrated equivalence to 12.5 mg/day rofecoxib for acute non-specific low back pain. Its active iridoid glycoside harpagoside inhibits NF-κB, COX-2, and iNOS inflammatory pathways.

DHA (docosahexaenoic acid), a long-chain omega-3 fatty acid, contributes to LBP reduction as part of fish oil supplementation in multiple RCTs. DHA serves as a precursor to D-series resolvins that resolve inflammation and is involved in attenuating IVD degeneration. An RCT of 36 women supplemented with fish oil (550 mg EPA + 205 mg DHA daily for 3 months) found marked reductions in low back pain.

EPA (eicosapentaenoic acid) has specific RCT evidence for pain relief in adults with lower back pain, as reported in a Mendelian randomization review (Frontiers in Nutrition 2022). EPA attenuates IVD degeneration by inducing autophagy and reducing endoplasmic reticulum stress in nucleus pulposus cells. It also reduces prostaglandin E2 synthesis and inflammatory cytokine production relevant to LBP pathophysiology.

Fish oil, as the primary dietary source of EPA and DHA, has RCT evidence for reducing low back pain. A 3-month RCT (n=36; 15 mL fish oil daily) found marked LBP reduction. A clinical trial (NCT02774109) studied 3000 mg/day fish oil with EPA and DHA for 8 weeks in chronic nonspecific LBP, and a 2006 Surgical Neurology study found reduced pain and NSAID use in neck/back pain patients after fish oil supplementation.

Ginger (Zingiber officinale) has been studied in RCTs for chronic low back pain, with a PMC narrative review of the last decade's RCTs confirming clinical use for dysmenorrhea, muscle soreness, osteoarthritis, and chronic LBP. Its mechanism involves inhibition of prostaglandin synthesis via COX and LOX pathways. A clinical trial involving aromatic ginger oil found efficacy in chronic LBP, and multiple studies show anti-inflammatory effects.

Glucosamine, a naturally occurring amino monosaccharide in cartilage, has been studied for spinal and joint pain including low back pain associated with disc degeneration and osteoarthritis. A study in Osteoarthritis and Cartilage found glucosamine and chondroitin can reduce pain and improve mobility in chronic back pain with degenerative disc disease. Mechanistically, glucosamine provides proteoglycan synthesis precursors for nucleus pulposus and articular cartilage.

Harpagoside is the primary active iridoid glycoside constituent of Devil's Claw standardized for clinical use in low back pain. The Cochrane review identified it as the standardization marker used in RCTs demonstrating pain reduction greater than placebo at daily doses of 50–100 mg. It inhibits NF-κB, COX-2, and iNOS signaling pathways associated with musculoskeletal inflammation.

Intervertebral disc (IVD) degeneration is a leading cause of low back pain, and HA is a natural component of the disc extracellular matrix. Intradiscal HA injection has been explored in early-phase human trials and preclinical models. High-molecular-weight HA has shown anti-inflammatory and analgesic properties in IVD models, though robust randomized controlled trials in humans remain limited. Oral HA for low back pain has only one identified clinical study to date.

Topical menthol products are used clinically for back pain relief, with counterirritant properties and sodium channel blockade providing temporary analgesia. Clinical evidence is derived from trials of menthol in musculoskeletal pain broadly, including back pain.

MSM (methylsulfonylmethane) has been studied in clinical trials for musculoskeletal pain, including osteoarthritis and specifically low back pain. A randomized double-blind placebo-controlled safety and efficacy trial (6 g/day MSM for 16 weeks) in LBP and osteoarthritis patients documented analgesic and anti-inflammatory effects. MSM combined with boswellic acids showed efficacy comparable to glucosamine sulfate for knee arthritis in a 120-patient RCT.

Omega-3 fatty acids (EPA and DHA) have multiple RCTs and a Mendelian randomization study (n=79,452) supporting their role in reducing low back pain. EPA and DHA attenuate intervertebral disc degeneration, reduce inflammatory cytokine production, and serve as precursors to pro-resolving mediators. A 2006 Surgical Neurology study found reduced pain and NSAID use in nonsurgical neck/back pain patients after fish oil supplementation.

Salicin (as standardized willow bark extract) has the strongest clinical evidence base of any condition studied. Multiple RCTs and a Cochrane review support its use for short-term relief of nonspecific low back pain, with a clear dose-response effect. The 240 mg/day salicin dose outperforms placebo significantly and performs comparably to rofecoxib (COX-2 inhibitor).

Serratiopeptidase is clinically indicated and prescribed for back pain in India, and is listed across multiple clinical references as an indicated condition. However, the Bhagat 2013 systematic review noted no dedicated studies on back pain were found, and the Wikipedia assessment confirms no randomized evidence specifically for back pain exists. Use is based on extrapolation from its anti-inflammatory/analgesic properties.

Turmeric (Curcuma longa) and its active curcuminoid fraction have been studied in RCTs for low back pain, including a double-blind placebo-controlled trial showing significant superiority of a turmeric-Boswellia formulation over placebo for acute LBP (p<0.001 for pain at rest, movement, and pressure pain). Curcumin inhibits COX-2, iNOS, NF-κB, and LOX pathways involved in spinal inflammation.

Vitamin D deficiency is consistently and significantly associated with increased low back pain severity, paraspinal muscle atrophy, and lumbar disc degeneration. A retrospective study (n=232 postmenopausal women) found severe deficiency correlated with higher VAS pain scores (p=0.002) and more severe disc degeneration at multiple lumbar levels. Mechanistically, vitamin D inhibits NF-κB and ferroptosis in nucleus pulposus cells and supports musculoskeletal function.

Vitamin D3 (cholecalciferol) is the biologically preferred form of vitamin D for supplementation in back pain. A randomized placebo-controlled trial studied 300,000 IU intramuscular vitamin D3 for discogenic pain in lumbar disc herniation. A comparative clinical trial found vitamin D3 supplementation significantly reduced VAS pain and IL-6 in adults with LBP versus untreated control, comparable to ginger extract.

White willow bark (Salix alba), containing salicin as its principal active compound, has moderate Cochrane-level evidence for short-term improvement in chronic low back pain. Two moderate-quality RCTs involving 261 participants found daily doses of 120–240 mg salicin superior to placebo for pain and rescue medication use. A dose of 240 mg salicin daily was comparable in efficacy to 12.5 mg/day rofecoxib.

Willow bark has the strongest clinical evidence for low back pain among all its indicated uses. A landmark RCT (Chrubasik et al., Am J Med 2000, n=191) showed a dose-dependent analgesic effect, with 39% of the high-dose group (240 mg salicin/day) pain-free in the final week vs. 6% on placebo. A systematic review confirmed moderate evidence of effectiveness, finding its analgesic effect not inferior to rofecoxib. The EMA and ESCOP both formally recognize willow bark dry extract for short-term treatment of low back pain.

Wintergreen's active constituent, methyl salicylate, is FDA-recognized as a topical counterirritant and analgesic indicated for simple backache. A large real-world Phase IV trial (n=3,515) found compound methyl salicylate liniment significantly reduced soft tissue pain including in the back (mean VAS 5.34 vs 2.79, p<0.0001). Evidence for wintergreen oil alone—distinct from methyl salicylate preparations—is limited, with no dedicated RCTs on wintergreen oil as an isolate.

Epimedium has a classical TCM indication for soreness and weakness of the back and knees, attributed to kidney yang deficiency. The Compendium of Materia Medica records its use to nourish essence, strengthen tendons and bones, and tonify the waist and knees. No clinical trials specifically targeting backache as a primary endpoint have been conducted.

In Traditional Chinese Medicine (TCM), dodder seed (Tu Si Zi) is a classic remedy for lower back pain attributed to kidney-yang deficiency. TCM materia medica texts describe it as treating 'aching and weakness of the loins and knees.' European folk traditions also used dodder as an analgesic for back and joint pain. No controlled human clinical trials isolating dodder for backache have been published.

Lower back pain (lumbago) is the primary classical indication for eucommia bark in TCM, documented in the Shennong Herbal Classic and the Chinese Pharmacopoeia. It is attributed to 'kidney yang deficiency' in TCM theory. No placebo-controlled human RCTs specifically for backache have been identified.

In TCM, Gentiana macrophylla is used for wind-damp musculoskeletal pain including back pain, scapulohumeral periarthritis, and lumbar complaints. The Phytomedicine review of Radix Gentianae Macrophyllae documents its traditional indication for 'scapulohumeral periarthritis' alongside arthritis and stroke. Its anti-inflammatory and analgesic properties provide pharmacological plausibility.

Gravel root has a documented traditional use for backache, particularly when the pain is attributed to renal or urinary causes such as kidney stones or bladder irritation. Herbalists have included it in formulas targeting kidney-related back pain. No clinical trials have assessed this use specifically.

Traditional Chinese medicine uses Impatiens stems and roots specifically for lumbago (lower back pain) and neuralgia. This use is documented in multiple ethnobotanical reviews and supported by the plant's general antinociceptive pharmacology, though no clinical studies exist.

Common milkweed (Asclepias syriaca) was used by multiple Indigenous peoples of North America to treat backache and lumbago. This use is documented in ethnobotanical records from tribes such as those of the mid-Atlantic and Midwest. A 19th-century medical journal entry from 1888 specifically references A. syriaca for lumbago. No clinical trials have investigated this indication.

Ethnobotanical records document that the Kawaiisu people of North America used a decoction of Mimulus guttatus stems and leaves as a herbal steam bath for chest and back soreness. This is a physical folk medicine use distinct from the Bach flower remedy tradition. No clinical or preclinical research has examined this application.

Mustard plasters are traditionally applied to the back for relief of backache and muscle pain, exploiting the rubefacient and counterirritant properties of AITC. This is a well-documented folk remedy with a long history in Western and South Asian medicine, though no controlled human trials exist specifically for backache.

Lower back soreness and weakness is a well-documented traditional TCM indication for Ligustrum lucidum, associated with liver-kidney yin deficiency. The 2020 Chinese Pharmacopoeia includes 'invigorating muscles and bones' among its functions. No clinical trial evidence exists for this specific indication.

The EMA's HMPC Committee recognizes queen of the meadow as a traditional herbal medicinal product for the relief of minor joint pain including lower back pain. This recognition is based on documented traditional use, not clinical trial evidence. The salicylate content of the plant provides a plausible analgesic mechanism.

Rose hip has documented traditional use for back pain in European herbal medicine, listed by RxList and Restorative Medicine's monograph as a traditional application for back and leg pain. The anti-inflammatory mechanisms documented in rose hip for joint conditions (COX inhibition, cytokine reduction) provide pharmacological plausibility for this traditional use.

Solomon's seal is documented in TCM, Ayurvedic, and Western herbal traditions for back pain relief, attributed to its connective-tissue tonifying and anti-inflammatory actions on vertebral tendons, ligaments, and spinal discs. Drugs.com (citing Zhao 2018) lists backache as a traditional indication across multiple Polygonatum traditions.

Traditional use of spruce bark steam baths and resin plasters for backache and lumbago is documented in Native North American and European ethnobotanical records. Alaskan traditional medicine describes spreading pitch on canvas and applying it to a sore back. Spruce needle oil in bath and topical application is also noted for musculoskeletal pain including the back.

Teasel root (Dipsacus asper, known as Xu Duan in TCM) has a long-standing traditional use for lower back pain, particularly pain associated with kidney and liver deficiency in the TCM framework. It is traditionally used to strengthen the lower back and knees and fortify bones and sinews. No controlled human clinical trials have been conducted specifically for this indication.

Lumbago (lower back pain) is consistently listed across multiple TCM monographs, ethnomedicinal surveys, and pharmacopeial formulas as an indication for X. strumarium. The plant's analgesic and anti-inflammatory properties support this use mechanistically. No clinical studies targeting lumbago specifically have been published.